Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Modified FOLFOX in Advanced Hepatocellular Carcinoma
NCT01775501Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2013
- Primary completion
- Jul 2018
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib, oxaliplatin, fluorouracil, folinic acid in hepatocellular carcinoma (HCC), sponsored by Massachusetts General Hospital. Started Jan 2013; status: completed.
02
Drugs
sorafeniboxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01775501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01775501.